As well as this, in a mouse model of human nonalcoholic steatohepatitis (NASH), canagliflozin shows benefits reducing liver inflammation and fibrosis by reducing macrophage infiltration and the M1/M2 macrophage ratio, and decreasing NFκB activity, alleviating acute heart injury [184]. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.